Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-211 in recurrent small cell lung cancer
NCT00046787Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2002
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
A Phase 2 trial of lurtotecan liposome in small cell lung cancer (SCLC), sponsored by Astellas Pharma. Started Sep 2002; status: completed.
02
Drugs
lurtotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00046787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046787.